At a Glance
- CD34+ cell therapy platform yielding a multi-product development pipeline with 2 clinical programs having regenerative medicine “breakthrough” designation
- Proprietary field-leading technology in lucrative global indications backed by a strong IP portfolio
- Multiple potential value creating events in the next 12-24 months based on milestones across the pipeline
- Strong balance sheet; ~$116 million in cash & investments (2/25/2021) with no debt and cash runway projected to fund operations for several years
- Seasoned management with noteworthy domain expertise along with big pharma and emerging biotech experience
Maximum 30 minute delay for quote.